Corcept Therapeutics (CORT) Upgraded Following FDA Approval of Lifyorli for Ovarian Cancer
Corcept Therapeutics (NASDAQ:CORT) received a regulatory upgrade from Wolfe Research to Peerperform following the FDA's approval of its drug Lifyorli in combination with nab-paclitaxel for platinum-resistant ovarian cancer. The Phase 3 ROSELLA study showed patients had a 35% lower risk of death and a 30% reduced disease progression compared to monotherapy.
Tickers: $CORT
Topics: biotech drug approval oncology stock upgrade